Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 4, 2026, 6:20 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1561–1584 of 1,719 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Positive control Clear all

Conditions: Geriatric, Chronic Pain
Interventions: LARKSPUR; Behavioral
Lead sponsor: Weill Medical College of Cornell University; Other
Eligibility: 50 Years and older
Enrollment: 95 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: New York, New York

Conditions: COVID-19, Burnout, Burnout, Professional, Work-related Illness, Work-Related Stress, SARS-CoV-2 Infection
Interventions: Positive Affect Regulation sKills (PARK); Behavioral
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years and older
Enrollment: 555 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Advanced HER2+Breast Cancer
Interventions: Alpelisib, Alpelisib matching Placebo, Trastuzumab, Pertuzumab; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 100 Years
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 2
States / cities: Fayetteville, Arkansas • Los Angeles, California

Conditions: Parenting, Development, Child
Interventions: Sit Down and Play, Child Safety Handout; Behavioral · Other
Lead sponsor: University of Illinois Chicago; Other
Eligibility: 2 Months to 3 Months
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2022
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: SARS-CoV2 Infection
Interventions: Rapid Antigen Screening Test; Device
Lead sponsor: Columbia University; Other
Eligibility: 2 Years and older
Enrollment: 337 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: New York, New York

Conditions: Respiratory Syncytial Viruses
Interventions: ABRYSVO Vaccination; Biological
Lead sponsor: Pfizer; Industry
Eligibility: 0 Months to 6 Months
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: New York, New York

Conditions: Knee Osteoarthritis
Interventions: Transcutaneous Electrical Nerve Stimulation, Physical Therapy Exercises, No Intervention; Other
Lead sponsor: Creighton University; Other
Eligibility: 19 Years to 65 Years
Enrollment: 61 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: Omaha, Nebraska

Conditions: Breast Cancer
Interventions: Axillary lymph node dissection (ALND), Axillary radiotherapy (ART); Procedure
Lead sponsor: University Hospital, Basel, Switzerland; Other
Eligibility: 18 Years and older
Enrollment: 1,060 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2037
U.S. locations: 3
States / cities: Bethesda, Maryland • Durham, North Carolina • Philadelphia, Pennsylvania

Conditions: Infectious Endocarditis
Interventions: Accelerated treatment of endocarditis, Usual guideline therapy; Other
Lead sponsor: Copenhagen University Hospital, Rigshospitalet; Other
Eligibility: 18 Years and older
Enrollment: 508 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2036
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: HIV Positive
Interventions: Not listed
Lead sponsor: QIAGEN Gaithersburg, Inc; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 57 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Asthma
Interventions: PEF Feedback, Asthma education; Behavioral
Lead sponsor: Icahn School of Medicine at Mount Sinai; Other
Eligibility: 60 Years and older
Enrollment: 58 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 3
States / cities: New York, New York • The Bronx, New York

Conditions: Allergic Rhinitis
Interventions: CryJ2-DNA-LAMP plasmid vaccine by intradermal injection, Saline Control; Biological · Other
Lead sponsor: Immunomic Therapeutics, Inc.; Industry
Eligibility: 18 Years to 63 Years
Enrollment: 22 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Honolulu, Hawaii

Conditions: Autism Disorder
Interventions: Autism Parent Trainer (APT), Teaching Routines (Control); Behavioral
Lead sponsor: IRIS Media Inc; Other
Eligibility: 18 Years and older
Enrollment: 156 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Eugene, Oregon

Conditions: HIV Infections
Interventions: Celgosivir hydrochloride; Drug
Lead sponsor: Hoechst Marion Roussel; Industry
Eligibility: 18 Years to 50 Years
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Breast Cancer
Interventions: Everolimus, Placebo, Trastuzumab, Paclitaxel; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 719 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2017
U.S. locations: 25
States / cities: Mobile, Alabama • Chandler, Arizona • Fayetteville, Arkansas + 21 more

Conditions: HIV Infections
Interventions: Indinavir sulfate, Abacavir sulfate, Amprenavir, Nelfinavir mesylate, Efavirenz, Levocarnitine, Adefovir dipivoxil, Saquinavir; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 13 Years and older
Enrollment: 475 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 2000
U.S. locations: 44
States / cities: Los Angeles, California • Menlo Park, California • San Diego, California + 27 more

Conditions: Non-Squamous Non-Small Cell Lung Cancer
Interventions: Erlotinib, Onartuzumab (MetMab), Placebo; Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 494 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 56
States / cities: Chandler, Arizona • Hayward, California • Modesto, California + 47 more

Conditions: Squamous Cell Carcinoma of the Oropharynx, HPV16 Positive
Interventions: ISA101b, Cemiplimab, Placebo; Biological · Drug · Other
Lead sponsor: ISA Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 194 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2025
U.S. locations: 10
States / cities: Duarte, California • San Diego, California • San Francisco, California + 7 more

Conditions: Depression
Interventions: Keto-like supplement, Placebo; Dietary Supplement
Lead sponsor: Laureate Institute for Brain Research, Inc.; Other
Eligibility: 18 Years to 65 Years
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Tulsa, Oklahoma

Conditions: CHLAMYDIA INFECTIONS
Interventions: No intervention, only observational; Other
Lead sponsor: Arkansas Children's Hospital Research Institute; Other
Eligibility: 11 Years to 21 Years · Female only
Enrollment: 29 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2016
U.S. locations: 1
States / cities: Little Rock, Arkansas

Conditions: Stress, Psychological, Stress, Emotional, Stress, Physiological
Interventions: Ethnic and Racial Identity Promotion, Academic Skills Promotion; Behavioral
Lead sponsor: Northwestern University; Other
Eligibility: 13 Years to 18 Years
Enrollment: 400 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2032
U.S. locations: 3
States / cities: Evanston, Illinois • Niles, Illinois

Conditions: Alcohol Abuse, Alcohol Dependence
Interventions: Motivational Interview, Assessment; Behavioral
Lead sponsor: Brown University; Other
Eligibility: 18 Years and older
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2011
U.S. locations: 2
States / cities: Providence, Rhode Island

Conditions: Breast Neoplasms
Interventions: Xentuzumab, Placebo, Everolimus, Exemestane; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 103 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 16
States / cities: Chandler, Arizona • Goodyear, Arizona • Beverly Hills, California + 13 more

Conditions: Multiple Sclerosis
Interventions: Not listed
Lead sponsor: University of Pittsburgh; Other
Eligibility: 7 Years and older
Enrollment: 7,500 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2047
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Search by objective public record fields.

Positive Affect as a Source of Resilience for Adults in Chronic Pain

Psychological Well-being and Burnout in Healthcare Workers During the COVID-19 (Coronavirus Disease 2019) Pandemic

Study of Alpelisib (BYL719) in Combination With Trastuzumab and Pertuzumab as Maintenance Therapy in Patients With HER2-positive Advanced Breast Cancer With a PIK3CA Mutation

Child Development and Primary Care in Low Income Families

COVID-19 SARS-CoV-2 RAST Study

Effectiveness of ABRYSVO® Maternal Respiratory Syncytial Virus (RSV) Vaccine Against RSV in Infants in Western Pennsylvania

Corticospinal Excitability and Rehab in Knee Osteoarthritis

Axillary Radiotherapy or Axillary Lymph Node Dissection in Patients With Clinically Node- Positive Breast Cancer Undergoing Upfront Tailored Axillary Surgery

Accelerated Treatment of Endocarditis

Evaluation of a Blood Test to Measure Immune Function in HIV Positive People Compared With HIV Negative People

Symptom Perception

A Safety and Immunogenicity Phase IC Study of CryJ2 -DNA-LAMP Plasmid Vaccine for Assessment of Intradermal (ID) Route of Administration Using the Biojector 2000 Device

ASD Parent Trainer: Online Coaching for Parents of Children With Autism

A Study of MDL 28,574A in HIV-Infected Patients

Everolimus in Combination With Trastuzumab and Paclitaxel in the Treatment of HER2 Positive Locally Advanced or Metastatic Breast Cancer

A Study on Amprenavir in Combination With Other Anti-HIV Drugs in HIV-Positive Patients

A Study of Onartuzumab (MetMAb) in Combination With Tarceva (Erlotinib) in Participants With Met Diagnostic-Positive Non-Small Cell Lung Cancer Who Have Received Chemotherapy For Advanced or Metastatic Disease (MetLung)

A Randomized Phase 2 Study of Cemiplimab ± ISA101b in HPV16-Positive OPC

Evaluation of a Keto-Like Supplement on Brain Responses to Emotional Stimuli in Depression

Immunopathogenesis of Chlamydia

Biology, Identity & Opportunity Study

Enhanced Motivational Interviewing With Alcohol Positive Trauma Patients

The XENERA™ 1 Study Tests Xentuzumab in Combination With Everolimus and Exemestane in Women With Hormone Receptor Positive and HER2-negative Breast Cancer That Has Spread

Prospective Investigation of Multiple Sclerosis in the Three Rivers Region